Literature DB >> 30526897

Clinical features and structured clinical evaluation of vasculitis.

C Ponte1, A F Águeda2, R A Luqmani3.   

Abstract

Systemic vasculitides are a group of heterogeneous conditions with overlapping patterns of clinical and laboratory manifestations. Moreover, clinical features can be non-specific and seemingly disparate. A major factor in defining optimal therapy and measuring treatment response is careful disease assessment targeting four main domains: activity, damage, prognosis and quality of life/function. Assessment tools such as the Birmingham Activity Score and the Vasculitis Damage Index have become a core feature of clinical trials in ANCA-associated vasculitis (AAV) and formed the basis for sound clinical management of these complex conditions. We are still lacking accurate definitions of disease activity and damage progression in large-vessel vasculitis. There is an increasing interest in the role of patient-reported outcomes as a measure of disease impact; a disease-specific measure for use in AAV is being validated. We review how best to evaluate patients with large-, medium- and small-vessel vasculitis.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  ANCA-Associated vasculitis; Damage; Disease activity; Disease assessment; Giant cell arteritis; Patient-reported outcomes; Prognosis; Quality of life; Takayasu arteritis; Vasculitis

Mesh:

Year:  2018        PMID: 30526897     DOI: 10.1016/j.berh.2018.10.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  2 in total

1.  Increased Urinary CD163 Levels in Systemic Vasculitis with Renal Involvement.

Authors:  Xiayire Aierken; Qing Zhu; Ting Wu; Sha Sha Liu; Yuan Yuan Cao; Xin Tian Cai; Ayiguzaili Aihemaiti; Yunwei Bi; Shunfan Yang; Weiwei Zhang; Nanfang Li
Journal:  Biomed Res Int       Date:  2021-04-30       Impact factor: 3.411

Review 2.  The Impact of High Dose Glucocorticoids on Bone Health and Fracture Risk in Systemic Vasculitides.

Authors:  Christopher David Box; Owen Cronin; Barbara Hauser
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-16       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.